PD-1/PD-L1 interaction
PD-1/PD-L1 interaction(PD-1/PD-L1 相互作用)
Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.
Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.
In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.
PD-1/PD-L1 interaction 相关产品(90)
- GC15142PD-1/PD-L1 inhibitor 1 (BMS-1)CAS: 1675201-83-8纯度: >99.50%
PD-1/PD-L1 inhibitor 1 是一种 PD-1/PD-L1 相互作用抑制剂，IC50 值介于 6 和 100 nM . PD-1/PD-L1 调节细胞信号通路和表观遗传修饰，从而抑制 T 细胞和 B 细胞的增殖和效应子功能。
- GC19225PD-1-IN-1 (CA-170)CAS: 1673534-76-3纯度: >99.00% / >98.00%
PD-1-IN-1 (CA-170) 是一种具有口服活性的免疫检查点调节蛋白VISTA和PD-L1双重抑制剂。
- GC19531PembrolizumabCAS: 1374853-91-4纯度: >99.00% / >98.00%
Pembrolizumab 是一种抗程序性死亡 1 单克隆抗体，已在晚期实体癌患者中证明具有临床显着的抗肿瘤活性和可接受的安全性，并已被美国 FDA 批准用于治疗晚期黑色素瘤、NSCLC、头颅和脑肿瘤。
- GC31719Avelumab (Anti-Human PD-L1, Human Antibody)CAS: 1537032-82-8纯度: >99.00% / >95.00% / >97.00%
Avelumab (Anti-Human PD-L1, Human Antibody)是一种静脉给药的完全人源化IgG1单克隆抗体。
- GC32704Atezolizumab (MPDL3280A)CAS: 1380723-44-3纯度: >98.50% / >99.00% / >95.00%
Atezolizumab 是一种针对 PD-L1 的特异性单克隆抗体，可以抑制 PD-L1 和 PD-1 之间的结合。
- GC34218Nivolumab (BMS-936558)CAS: 946414-94-4纯度: >98.50%
Nivolumab 是一种抗癌单克隆抗体，是一种程序性死亡受体-1 阻断人 IgG4 抗体，用于治疗晚期（转移性）非小细胞肺癌。
- GC35913DurvalumabCAS: 1428935-60-7纯度: >99.50%
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
- GC36768NP-12 (TFA)
NP-12 (TFA) 是 PD-1 信号通路的一种多肽拮抗剂，在抑制淋巴细胞增殖和效应功能方面对 PD-L1 和 PD-L2 具有等效的拮抗作用。NP-12 (TFA) 具有免疫激活作用、良好的抗肿瘤活性，具有治疗免疫相关不良事件 (irAEs) 的潜力。
- GC36862PD-1-IN-22CAS: 2349372-98-9
PD-1-IN-22 是一种有效的程序性细胞死亡 1 (PD-1)/程序性细胞死亡配体1 (PD-L1) 相互作用的抑制剂，IC50 为 92.3 nM。
- GC38044FraxinelloneCAS: 28808-62-0纯度: >99.50%
A liminoid degradant with diverse biological activities
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC16762 | BMS-202 | 1675203-84-5 | >99.00% | |
BMS-202是一种非肽性PD-1/PD-L1复合物抑制剂，与PD-L1隔离PD-1/PD-L1二聚体形成（IC 50 =53.6nM），以结合阻断人PD-1/PD-L1相互作用，从而抑制免疫反应抑制，从而阻止癌细胞逃避抗肿瘤免疫反应。 | ||||
| GC10469 | Sulfamethoxypyridazine | 80-35-3 | >99.50% | |
A sulfonamide antibiotic | ||||
| GC15142 | PD-1/PD-L1 inhibitor 1 (BMS-1) | 1675201-83-8 | >99.50% | |
PD-1/PD-L1 inhibitor 1 是一种 PD-1/PD-L1 相互作用抑制剂，IC50 值介于 6 和 100 nM . PD-1/PD-L1 调节细胞信号通路和表观遗传修饰，从而抑制 T 细胞和 B 细胞的增殖和效应子功能。 | ||||
| GC16258 | PD-1/PD-L1 Inhibitor 3 | 1629654-95-0 | - | |
A PD-1/PD-L1 interaction inhibitor | ||||
| GC19131 | Tomivosertib | 1849590-01-7 | >98.00% | |
A potent inhibitor of MNK1 and MNK2 | ||||
| GC19225 | PD-1-IN-1 (CA-170) | 1673534-76-3 | >99.00% / >98.00% | |
PD-1-IN-1 (CA-170) 是一种具有口服活性的免疫检查点调节蛋白VISTA和PD-L1双重抑制剂。 | ||||
| GC19531 | Pembrolizumab | 1374853-91-4 | >99.00% / >98.00% | |
Pembrolizumab 是一种抗程序性死亡 1 单克隆抗体，已在晚期实体癌患者中证明具有临床显着的抗肿瘤活性和可接受的安全性，并已被美国 FDA 批准用于治疗晚期黑色素瘤、NSCLC、头颅和脑肿瘤。 | ||||
| GC25160 | BMS-1001 | 2113650-03-4 | - | |
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. | ||||
| GC31719 | Avelumab (Anti-Human PD-L1, Human Antibody) | 1537032-82-8 | >99.00% / >95.00% / >97.00% | |
Avelumab (Anti-Human PD-L1, Human Antibody)是一种静脉给药的完全人源化IgG1单克隆抗体。 | ||||
| GC31753 | BMS-1166 (PD-1/PD-L1-IN1) | 1818314-88-3 | >98.00% | |
A PD-1/PD-L1 interaction inhibitor | ||||
| GC31878 | PD1-IN-2 | 1673534-97-8 | - | |
PD1-IN-2 是一种 PD1 信号通路抑制剂，可作为免疫调节剂。 | ||||
| GC32704 | Atezolizumab (MPDL3280A) | 1380723-44-3 | >98.50% / >99.00% / >95.00% | |
Atezolizumab 是一种针对 PD-L1 的特异性单克隆抗体，可以抑制 PD-L1 和 PD-1 之间的结合。 | ||||
| GC34218 | Nivolumab (BMS-936558) | 946414-94-4 | >98.50% | |
Nivolumab 是一种抗癌单克隆抗体，是一种程序性死亡受体-1 阻断人 IgG4 抗体，用于治疗晚期（转移性）非小细胞肺癌。 | ||||
| GC34928 | PD-1-IN-17 | 1673560-66-1 | - | |
An inhibitor of PD-1 signaling | ||||
| GC34929 | PD-1-IN-17 TFA | - | - | |
An inhibitor of PD-1 signaling | ||||
| GC35913 | Durvalumab | 1428935-60-7 | >99.50% | |
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa. | ||||
| GC36767 | NP-12 | 1353563-85-5 | - | |
A PL-1/PD-L interaction inhibitor | ||||
| GC36768 | NP-12 (TFA) | - | - | |
NP-12 (TFA) 是 PD-1 信号通路的一种多肽拮抗剂，在抑制淋巴细胞增殖和效应功能方面对 PD-L1 和 PD-L2 具有等效的拮抗作用。NP-12 (TFA) 具有免疫激活作用、良好的抗肿瘤活性，具有治疗免疫相关不良事件 (irAEs) 的潜力。 | ||||
| GC36862 | PD-1-IN-22 | 2349372-98-9 | - | |
PD-1-IN-22 是一种有效的程序性细胞死亡 1 (PD-1)/程序性细胞死亡配体1 (PD-L1) 相互作用的抑制剂，IC50 为 92.3 nM。 | ||||
| GC38044 | Fraxinellone | 28808-62-0 | >99.50% | |
A liminoid degradant with diverse biological activities | ||||
| GC38131 | BMS-1166 hydrochloride | 2113650-05-6 | - | |
A PD-1/PD-L1 interaction inhibitor | ||||
| GC38740 | BMS-1001 hydrochloride | 2113650-04-5 | >98.00% | |
An inhibitor of the PD-1/PD-L1 interaction | ||||
| GC50482 | (D)-PPA 1 | 1620813-53-7 | - | |
An inhibitor of the PD-1-PD-L1 protein-protein interaction | ||||
| GC61946 | TPP-1 | 2426685-25-6 | >96.50% | |
TPP-1 是 PD-1/PD-L1 相互作用的有效抑制剂。TPP-1 与 PD-L1 特异性高亲和力结合 (KD=95 nM)。动物模型中，TPP-1 通过再激活 T 细胞功能抑制肿瘤生长。 | ||||